Diplopia

Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.

Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.

CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.

Adults with thyroid eye disease and diabetes have a higher prevalence of diplopia, strabismus and sight-threatening disease compared with those without diabetes, according to study findings published in Endocrine Practice.

An 11-year-old boy presented to the University of New Mexico Hospital with 6 weeks of vomiting and food intolerance as well as a 13-pound weight loss over that same period.

Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.

A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months of progressive diplopia, bilateral eye redness and proptosis.

Thyroid eye disease was first described by Robert James Graves, FRCS, an Irish surgeon who recognized the association of hyperthyroidism with exophthalmos in 1835. Even today, many use Graves’ ophthalmopathy when discussing this disease.

A 63-year-old woman with diabetes, high blood pressure, depression and ovarian cysts presented to New England Eye Center for worsening diplopia for a few months.

A 45-year-old woman was admitted to the neurology service at Lahey Hospital and Medical Center with symptoms of double vision, gait disturbance secondary to lower extremity weakness and subjective memory loss.